Anti-idiotype cancer vaccine 1A7 (Titan)

N/A

Report date: 2022/03/17 14:35:10

Base Information

Drug NameAnti-idiotype cancer vaccine 1A7 (Titan)
Drug Alias Name1A7TriGemanti-Id antibody 1A7GD2 anti-idiotype cancer vaccine - Titan
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsDisialoganglioside GD2 modulators
TargetsDisialoganglioside GD2
Therapy Area/IndicationsMelanomaNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTitan Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTitan Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMelanomaNeuroblastoma

Other Information

ATC CodeN/A
Related LinksN/A